文献速递膀胱癌与上尿路尿路上皮癌

帕博利珠单抗联合吉西他滨与同步大分割放疗作为肌层浸润性膀胱癌保膀胱治疗的多中心2期试验

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.
PubMed 文献 · Eur Urol · 2026-04-06

这项多中心2期试验评估了在三联治疗(TMT)中加入帕博利珠单抗治疗肌层浸润性膀胱癌(MIBC)的安全性和疗效。结论认为该方案可行且疗效与标准TMT相当。

要点

  • 帕博利珠单抗联合吉西他滨放化疗的2年BIDFS率为60%。
  • 2年无转移生存率和总生存率分别为81%和83%。
  • ≥3级治疗相关不良事件发生率为25%,方案可行。

核心结论

  • 帕博利珠单抗联合基于吉西他滨的放化疗作为保膀胱治疗可行,疗效与标准TMT相当。

研究设计与样本

  • 患者接受一剂帕博利珠单抗后行最大程度经尿道切除,随后接受根治性膀胱放疗同步低剂量吉西他滨和帕博利珠单抗每3周共三剂。
  • 主要终点为2年膀胱完整无病生存(BIDFS),次要终点包括安全性、无转移生存(MFS)和总生存(OS)。

主要发现

  • 2年BIDFS率为60%(95%CI 45-73)。
  • 2年MFS率为81%(95%CI 66-92),2年OS率为83%(95%CI 69-91)。
  • ≥3级治疗相关不良事件发生率为25%。
  • 67%的患者为临床T2期疾病。

临床怎么用

  • 该联合方案可作为肌层浸润性膀胱癌保膀胱治疗的可行选择,疗效与标准TMT相当。
  • 需关注≥3级治疗相关不良事件,发生率为25%。
  • 正在进行的3期试验将进一步明确其在保膀胱治疗中的作用。

局限性

  • 单臂设计。
  • 样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Trimodality therapy (TMT) is an accepted bladder-preserving option for selected patients with muscle-invasive bladder cancer (MIBC). Pembrolizumab has demonstrated activity in MIBC and may enhance the effects of chemotherapy and radiation. We evaluated the safety and efficacy of adding pembrolizumab to TMT. METHODS: In this multicenter phase 2 trial, patients with MIBC received one dose of pembrolizumab followed by maximal transurethral resection, then definitive bladder radiation with concurrent low-dose gemcitabine and pembrolizumab every 3 wk for three doses. The primary end point was 2-yr bladder-intact disease-free survival (BIDFS). Secondary end points included safety, metastasis-free survival (MFS), and overall survival (OS). KEY FINDINGS AND LIMITATIONS: Fifty-four patients were enrolled, including 48 in the efficacy cohort; 67% had clinical stage T2 disease. The 2-yr BIDFS was 60% (95% confidence interval [CI], 45-73). Two-yr MFS and OS were 81% (95% CI, 66-92) and 83% (95% CI, 69-91), respectively. Grade ≥3 treatment-related adverse events occurred in 25% of patients. Limitations include the single-arm design and modest sample size. CONCLUSIONS AND CLINICAL IMPLICATIONS: Pembrolizumab combined with gemcitabine-based chemoradiation was feasible and showed efficacy comparable to standard TMT. Ongoing phase 3 trials will further define its role in bladder preservation.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Economides MP, O'Donnell PH, Alva AS, et al. Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial. Eur Urol. 2026. PMID: 41945031. doi:10.1016/j.eururo.2026.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。